Ajax Therapeutics CEO Martin Vogelbaum (L) and co-founder Ross Levine
May 13, 2024 07:00 AM EDT
Financing
Startups

'At­tack JAK': Ajax se­cures $95M to test new JAK2 in­hibitor af­ter in­dus­try's string of myelofi­bro­sis deals

Kyle LaHucik

Senior Reporter

A large phar­ma com­pa­ny want­ed to buy Ajax Ther­a­peu­tics when it was rais­ing a $40 mil­lion Se­ries B in 2021. But the start­up thought it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times